SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants

Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies

(2016) Eric Lawitz et al.   ANTIVIRAL THERAPY

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

(2016) Christoph Sarrazin et al.   GASTROENTEROLOGY

Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B

(2016) Kyle E. Korolowicz et al.   PLoS One

Development and validation of a “capture-fusion” model to study drug sensitivity of patient-derived hepatitis C

(2015) Morven E. Cunningham et al.   HEPATOLOGY

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

(2015) Graham R. Foster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

(2015) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

APOBECs and virus restriction

(2015) Reuben S. Harris et al.   VIROLOGY

Interferon-Stimulated Genes: A Complex Web of Host Defenses

(2014) William M. Schneider et al.   Annual Review of Immunology

Novel restriction factor RNA-associated early-stage anti-viral factor (REAF) inhibits human and simian immunodeficiency viruses

(2014) Kelly M Marno et al.   Retrovirology

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(2009) S. A. Bustin et al.   CLINICAL CHEMISTRY

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS